REGULATORY

• MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
  November 7, 2025

• Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
  November 6, 2025

• Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
  November 6, 2025

• MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
  November 6, 2025

• Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
  November 6, 2025

• Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
  November 6, 2025

• Tepid Exchanges at Chuikyo over Public-Private Working Group Report
  November 6, 2025

• Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
  November 6, 2025

• Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
  November 5, 2025

• MHLW Clarifies When Generic Drug Mergers Must Be Reviewed by Antitrust Regulator
  November 5, 2025

• LDP Project Team Urges Economic Measures Reflecting Price Pressures
  November 4, 2025

• Former Flagship Brands among 506 Drugs Set for Delisting
  November 4, 2025

• Anticoagulants and Other Drugs under PMDA Safety Review
  November 4, 2025

• Health Minister Vows to Balance Public Burden, Innovation, and Supply in FY2026 Revision
  October 31, 2025

• LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
  October 31, 2025

• Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
  October 31, 2025

• Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
  October 30, 2025

• Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
  October 30, 2025

• Japan to Delist 506 Drugs from NHI Price List, Including Category A Products and LLPs
  October 30, 2025

• Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
  October 30, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• …
• Next ›
• 最終 »